StockWatch
·
INOX INDIA · Q2 FY27 · THE VERDICT

Record backlog masks the execution test ahead

Revenue growth crushed guidance at 27.4%, but profit growth lagged at just 9.4% — margin compression from freight and strategic pricing reveals the real pressure. An ₹2,268 crore order backlog is genuine, but execution risk is the near-term overhang.

Q2 FY27 resultsINOXINDIAINOX India Ltd07 Nov 2026 · 6 min read
Revenue

₹456.5 Cr

+27.4% YoY; beat 18–20% FY27 guidance

PAT

₹66.6 Cr

+9.4% YoY; growth lags revenue by 3x

EBITDA margin

21.3%

–110 bps YoY; within 21–24% band but lower end

Order backlog

₹2,268 Cr

All-time high; 5+ year revenue visibility

INOX reported a headline beat on revenue — ₹456.5 crore, up 27.4% year-on-year, well above the 18–20% FY27 guidance range. But profit growth tells a different story. Net profit ₹66.6 crore was up only 9.4% YoY. The gap between revenue acceleration and profit deceleration is the quarter's defining tension. EBITDA margin fell to 21.3% in Q2, down 110 basis points, pulling the half-year margin to 22.3% — within guidance but at the lower bound. Management attributed this to freight costs and geopolitical uncertainty. But the call revealed a second, structural driver: strategic pricing on large orders to win the ₹1,100 crore space backlog from a U.S. aerospace customer. That's not temporary. It's a margin trade-off for scale, and it signals execution pressure is real.

The order book did double — but concentration is the catch

The headline from the call is the order backlog: ₹2,268 crore, an all-time high. This is genuinely impressive — 5+ years of revenue visibility at current run rates. But three facts temper enthusiasm. First, ~60–70% of the ₹1,100 crore space backlog is from a single U.S. aerospace customer. Management confirmed 10–15% execution in FY27, with 80–90% spilling to FY28. A program delay or cancellation is material risk. Second, roughly 50% of total backlog comes from 2–3 customers, all aerospace or defence-linked. Third, current capacity is stretched. Savli is near full utilisation. Kandla, the 50%-capacity expansion site, was originally due December 2026–January 2027. It's now March 2027 — a 2–3 month slip that signals execution pressure. Tighter-than-implied execution runway for H2 FY27.

Management claims vs. what holds up
Claim on the callActual numberVerdict
Order book crossed ₹2,200 Cr, highest in history₹2,268 Cr at Sept 30, 2026Supported
27.4% YoY revenue growth beats 18–20% FY27 guidance₹456.5 Cr revenue; guidance met and exceededSupported
EBITDA margin 21.3% within 21–24% guidance rangeQ2 21.3%, H1 22.3%; within band but lower endSupported
PAT growth 9.4% YoY indicates strong profitabilityRevenue +27.4%, PAT +9.4%; margin dilution evidentOverstated
Kandla facility commissioned Dec 2026–Jan 2027MD said March 2027; 2–3 month delayContradicted

What changed on this call

Key shifts from prior quarter
  • Order book doubled to ₹2,268 Cr; space sector ₹1,100 Cr confirmed (structural upgrade)

  • Kandla facility delayed from Dec-Jan to March 2027 (execution warning)

  • Margin compression now partly structural via strategic pricing, not just freight (recalibration)

  • Space customer 3–4 launch pads to commercialise by FY28; ISRO tenders live (de-risking)

  • New verticals scaling: Cryo-Scientific ₹35 Cr LIGO, semiconductors, beverage keg +446% YoY

How the street sees it

The stock stands at ₹1,870.2 (as of Nov 6), down 20% from its all-time high of ₹2,339.5 and trading below both the 20-day (₹1,950) and 50-day (₹2,053) moving averages. RSI sits at 41.6, neutral. This drawdown reflects the market's re-pricing of execution risk. Foreign institutional ownership is stable at 6.87%, down 0.26 percentage points this quarter — not active selling, but notably flat. Domestic institutions hold 7.67%, effectively unchanged. Promoters remain at 74.86%. The absence of large insider selling near the all-time high is a small positive. But price action signals the market is waiting to see whether H2 FY27 execution validates the backlog or signals further delays. Until Kandla is live and space execution is clarified quarter-by-quarter, uncertainty will cap the stock near current levels.

Risks ranked by holder concern

Customer concentration: 60–70% of space backlog from one U.S. aerospace customer; ~50% of total from 2–3 customers

High

Program delay or cancellation would materially impact FY28 revenue and profitability. Diversification to ISRO and private space underway but early.

Execution capacity constrained: ₹2,268 Cr backlog vs. ~₹450 Cr annual revenue; skilled labour scarcity; Kandla delayed

High

Tight capacity forced 'strategic pricing' on large orders; if execution slips further, Q3–Q4 margins compress or delivery delays trigger penalties.

Margin recovery timing uncertain: management expects H2 improvement as freight/geo headwinds ease, but structural pricing remains

Medium

If margins don't recover to 21–24% by Q3, confidence in FY28 profit growth erodes. PAT growth already lags revenue at 9.4% YoY.

Kandla commissioning delay (Dec-Jan → March 2027) signals execution pressure and constrains H2 capacity if orders accelerate

Medium

A further slip beyond March would force subcontracting or delivery delays, both margin headwinds or reputation risks.

New market scaling: Semiconductors, data centers early-stage; tender delays could push contributions to FY28+

Low

Currently small; upside optionality rather than near-term risk.

The bull-bear ledger

Key trade-offs
  • Record ₹2,268 Cr order backlog provides 5+ year visibility; space sector validated

  • Space customer 3–4 launch pads to commercialise by FY28; ISRO tenders live; structural tailwind

  • Debt-free ₹384 Cr net cash; no funding constraints for Kandla or capex

  • New verticals (LIGO ₹35 Cr, semiconductors, data centers) opening high-margin vectors

  • Revenue +27.4% crushes 18–20% guidance; execution has delivered to date

  • PAT +9.4% lags revenue; margin compression is structural, not one-time

  • EBITDA margin 21.3% at lower end of band; H1 22.3% still below historical 22–24% mid-point

  • Customer concentration: 60–70% of space backlog from one customer; ~50% of total from 2–3 customers

  • Kandla delayed; execution pressure evident in timeline slip and current capacity utilisation

What to watch next
  • 1 · Kandla commissioning (March 2027)

    On time delivery validates management credibility. Further delay signals execution is more constrained than portrayed. March 2027 is the credibility test.

  • 2 · Space order execution pace (Q3–Q4 FY27)

    10–15% of U.S. aerospace backlog in FY27, balance FY28. If orders slip or Q4 execution is weak, 2–3 year visibility becomes uncertain. Watch quarterly sequencing.

  • 3 · EBITDA margin trend (H2 FY27)

    Will margins recover to 22–24% or stabilise at 21–22%? This settles whether the 9.4% PAT growth gap vs. revenue is temporary or structural. Q3 print is decisive.

  • 4 · ISRO and semiconductor tenders (Q3–Q4)

    ISRO launch pad tender expected 2–3 weeks post-call, results in 4–6 weeks. Semiconductor fab projects in Gujarat; award sizing will signal diversification progress beyond aerospace.

The verdict

INOX has delivered a genuine beat on revenue growth. The ₹2,268 crore order backlog is real, and management is executing — Kandla is coming, ISRO tenders are live, new verticals are gaining traction. But this quarter exposed the pressure: executing on that backlog requires margin compression today, skilled labour shortages that the market hasn't resolved, and capex timelines that are slipping. The stock's 20% drawdown from the all-time high is not irrational — it reflects the market's re-pricing of execution risk. Holders are waiting to see whether H2 FY27 execution validates 18–20% growth and the margin band, or forces guidance revision downward. Until Kandla is live and U.S. aerospace 10–15% FY27 allocation is clarified sequentially, execution uncertainty will cap the stock near current levels. The rating is Hold on execution risk. The single metric to track is EBITDA margin trend. If Q3 comes in at 21.5%+ and H2 shows no Kandla slips, the case for re-rating up gains traction. Below 21%, margin guidance is in play and the backlog story becomes less attractive.

Informational and educational content only. Not investment advice.